A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. - Related Studies

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

This study has been completed.

Study NCT00077727. Last updated on March 17, 2008. Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Schizophrenia

2	More general conditions related to this trial
		Mental Disorders
		Schizophrenia and Disorders with Psychotic Features

3	Additional drug interventions recognized in this trial
		Galantamine

4	More general drug interventions related to this trial
		Autonomic Agents
		Central Nervous System Agents
		Cholinergic Agents
		Cholinesterase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Neurotransmitter Agents
		Nootropic Agents
		Parasympathomimetics
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

5	Sponsors listed in this trial
		Johnson &Johnson Pharmaceutical Research &Development, L.L.C.